Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 246

The DOI matches its Crossref record.

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Open access
Shi, Yuankai, Jia, Bo, Xu, Wei, Li, Wenyu, Liu, Ting, Liu, Peng, Zhao, Weili, Zhang, Huilai, Sun, Xiuhua, Yang, Haiyan, Zhang, Xi, Jin, Jie, Jin, Zhengming, Li, Zhiming, Qiu, Lugui, Dong, Mei, Huang, Xiaobing, Luo, Yi, Wang, Xiaodong, Wang, Xin, Wu, Jianqiu, Xu, Jingyan, Yi, Pingyong, Zhou, Jianfeng, He, Hongming, Liu, Lin, Shen, Jianzhen, Tang, Xiaoqiong, Wang, Jinghua, Yang, Jianmin, Zeng, Qingshu, Zhang, Zhihui, Cai, Zhen, Chen, Xiequn, Ding, Kaiyang, Hou, Ming, Huang, Huiqiang, Li, Xiaoling, Liang, Rong, Liu, Qifa, Song, Yuqin, Su, Hang, Gao, Yuhuan, Liu, Lihong, Luo, Jianmin, Su, Liping, Sun, Zimin, Tan, Huo, Wang, Huaqing, Wang, Jingwen, Wang, Shuye, Zhang, Hongyu, Zhang, Xiaohong, Zhou, Daobin, Bai, Ou, Wu, Gang, Zhang, Liling, Zhang, Yizhuo·2017·Journal of Hematology & Oncology

Abstract

The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). This study sought to further evaluate the real-world utilization of chidamide in 383 relapsed or refractory PTCL patients from April 2015 to February 2016 in mainland China. For patients receiving chidamide monotherapy (n = 256), the overall response rate (ORR) and disease control rate (DCR) were 39.06 and 64.45%, respectively. The ORR and DCR were 51.18 and 74.02%, respectively, for patients receiving chidamide combined with chemotherapy (n = 127). For patients receiving chidamide monotherapy and chidamide combined with chemotherapy, the median progression-free survival (PFS) was 129 (95% CI 82 to 194) days for the monotherapy group and 152 (95% CI 93 to 201) days for the combined therapy group (P = 0.3266). Most adverse events (AEs) were of grade 1 to 2. AEs of grade 3 or higher that occurred in ≥5% of patients receiving chidamide monotherapy included thrombocytopenia (10.2%) and neutropenia (6.2%). For patients receiving chidamide combined with chemotherapy, grade 3 to 4 AEs that occurred in ≥5% of patients included thrombocytopenia (18.1%), neutropenia (12.6%), anemia (7.1%), and fatigue (5.5%). This large real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile for refractory and relapsed PTCL patients. Chidamide combined with chemotherapy may be a new treatment choice for refractory and relapsed PTCL patients but requires further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-017-0439-6

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 246

Metadata

Authors
Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., Zhao, W., Zhang, H., Sun, X., Yang, H., Zhang, X., Jin, J., Jin, Z., Li, Z., Qiu, L., Dong, M., Huang, X., Luo, Y., Wang, X., Wang, X., Wu, J., Xu, J., Yi, P., Zhou, J., He, H., Liu, L., Shen, J., Tang, X., Wang, J., Yang, J., Zeng, Q., Zhang, Z., Cai, Z., Chen, X., Ding, K., Hou, M., Huang, H., Li, X., Liang, R., Liu, Q., Song, Y., Su, H., Gao, Y., Liu, L., Luo, J., Su, L., Sun, Z., Tan, H., Wang, H., Wang, J., Wang, S., Zhang, H., Zhang, X., Zhou, D., Bai, O., Wu, G., Zhang, L., & Zhang, Y.
Venue
Journal of Hematology & Oncology
Published
2017-03-15
Volume
10
Issue
1
Pages
69-69
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2601168549
Cited by
246
References
0
FWCI
11.13
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. https://app.cochat.ai/papers/10.1186/s13045-017-0439-6
The paper
Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., Zhao, W., Zhang, H., Sun, X., Yang, H., Zhang, X., Jin, J., Jin, Z., Li, Z., Qiu, L., Dong, M., Huang, X., Luo, Y., Wang, X., . . . Zhang, Y. (2017). Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-017-0439-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.